- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01122095
Cross-sectional Evaluation of Biological Markers of Cardiovascular Disease in Children and Adolescents With Psoriasis
Hypothesis 1: Patients with psoriasis will have clinical and laboratory assessments differing from control patients.
Hypothesis 2: Patients with psoriasis will have laboratory alterations that correlate with other clinical characteristics of their psoriasis.
Visão geral do estudo
Status
Condições
Descrição detalhada
Tipo de estudo
Inscrição (Antecipado)
Contactos e Locais
Locais de estudo
-
-
California
-
San Diego, California, Estados Unidos, 92123
- Recrutamento
- Rady Children's Hospital Dermatolgoy
-
Contato:
- Donna Pascual, LVN
- Número de telefone: 4295 858-576-1700
- E-mail: dpascual@rchsd.org
-
Contato:
- Ann Funk, RN, CCRC
- Número de telefone: 4295 858-576-1700
- E-mail: afunk@rchsd.org
-
Subinvestigador:
- Wynnis Tom, MD
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
Subjects of any race or ethnicity who meet all of the following criteria are eligible for enrollment into the study:
- The subject has a diagnosis of typical psoriasis, with or without arthritis, based on the clinical evaluation by an investigator or a prior diagnosis by a pediatric dermatologist
- Persons residing in the US.
- Subjects 0 to 18 years of age.
- Subjects/Guardians willing and able to comply with the requirements of the study.
- Subjects/Guardians willing and able to give informed consent.
- The subject is in general good health in the opinion of the investigator.
Exclusion Criteria:
- Over 18 years of age.
- Subject has had a diagnosis of congenital heart disease.
- Subject has had any cardiac catheterizations or surgeries.
- Subject has taken any cardiac medications (calcium channel blockers, beta blockers, vasotropic medicines) within the past 2 years.
- Subjects determined to have atypical psoriasis or isolated palmoplantar psoriasis.
- Subject diagnosed with any other systemic inflammatory disease including atopic dermatitis, severe acne vulgaris, inflammatory bowel disease, juvenile idiopathic arthritis, connective tissue disease and other similar conditions.
- Having autoimmune or immunodeficiency disease.
- Presence of active systemic fungal, bacterial, or viral infections.
- Presence of active systemic malignancy.
- Mental illness or history of drug or alcohol abuse that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements.
- Inability or unwillingness of a participant to give written informed consent.
Control Inclusion Criteria:
- Age up to 18 years.
- Ability and willingness to provide informed consent.
Control Exclusion Criteria:
- Over 18 years of age.
- Subject has had a diagnosis of congenital heart disease.
- Subject has had any cardiac catheterizations or surgeries.
- Subject has taken any cardiac medications (calcium channel blockers, beta blockers, vasotropic medicines) within the past 2 years.
- Subjects determined to have psoriasis of any type or a family history (first degree relative) with psoriasis.
- Subject diagnosed with any other systemic inflammatory disease including atopic dermatitis, severe acne vulgaris, inflammatory bowel disease, juvenile idiopathic arthritis, connective tissue disease and other similar conditions.
- Having autoimmune or immunodeficiency disease.
- Presence of active systemic fungal, bacterial, or viral infections.
- Presence of active systemic malignancy.
- Mental illness or history of drug or alcohol abuse that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements.
- Inability or unwillingness of a participant to give written informed consent.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
|---|
|
Psoriasis
Children with psoriasis Age matched controls without psoriasis or other significant inflammatory disease
|
|
Control patient
Age matched, without psoriasis or significant inflammatory disease
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Obesity risk assessment
Prazo: 6 months
|
Body Mass Index; C-reactive protein (CRP)
|
6 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Lawrence F. Eichenfield, MD, University of Calfornia, San Diego
Publicações e links úteis
Publicações Gerais
- 1. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB , Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006;55:829-35. 2. Gelfand J, Neimann A, Shin D et al. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296:1735-1741. 3. Gelfand J, Troxel B, Lewis J et al. The risk of mortality in patients with psoriasis: Results from a population-based study. Arch Dermatol. 2007;143(12):1493-1499 4. Kelishadi R, Ardalan G, Gheiratmand R, Adeli K, Delavari A, and Majdzadeh R et al. Pediatric metabolic syndrome and associated anthropometric indices: the CASPIAN study. Acta Paediatrica, 2006. 95: 1625-1634. 5. Goodman E, Dolan L, Morrison J and Daniels S. Factor Analysis of Clustered Cardiovascular Risks in Adolescence. Circulation 2005; 111: 1970-1977. 6. Schwimmer JB, Pardee PE, Lavine JE, Blumkin AK, Cook S. Cardiovascular Risk Factors and the Metabolic Syndrome in Pediatric Nonalcoholic Fatty Liver Disease. Circulation. 2008 June. 118:277-283.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 20080414
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .